AVM Biotechnology -- We know there is a better way



	Programs \| Vaccines \| Regenerative Medicine
	AVM Biotech’s Regenerative Medicine program is dedicated to developing enabling therapies that allow ethical stem cell treatments to realize their full clinical benefit. AVM Biotech certifies that its stem cell therapeutic products are not discovered, screened, evaluated, produced, or tainted in any way by the use of electively aborted human fetal material, human embryonic material, or any other unethically obtained materials. Adult and other morally acceptable stem cell therapies have advanced rapidly into clinical trials, driven primarily by the field of heart disease. Following closely behind the cardiovascular field are stem cell successes in type I diabetes, stroke, multiple sclerosis, muscular dystrophy, and other grievous illnesses. In heart disease, exciting results have been obtained, particularly in the ability of these stem cell treatments to reduce mortality and subsequent hospitalizations after a heart attack. Further improvements in recovery of function and increased quality-of-life after ethical stem cell treatments could be achieved through the development of therapies that 1) enhance the viability of the stem cells administered, 2) that allow for non-invasive delivery of stem cells, or 3) that increase retention of stem cells in the target organ. Regenerative medicine experts uniformly agree that advances in the above areas are essential in order to optimize current stem cell treatment outcomes. AVM Biotech has proprietary information and human capital, derived from Dr. Deisher’s 20 years of experience in pre-clinical research and clinical experience in the areas of heart failure and cardiac regeneration. Clinical target validation for AVM Biotech’s first regenerative medicine project has already been provided by ethical stem cell clinical trials completed by Helmut Drexler in heart attack patients.	Current stem cell treatments largely require the use of invasive and destructive stem cell delivery methods. For instance, stem cells must be directly injected into the heart using surgical methods or delivered into the coronary arteries using invasive catheter techniques, which are themselves damaging. Despite the use of these invasive and destructive delivery methods, only a small percentage of stem cells are retained within the target organ (generally less than 5%). Animal research has demonstrated that the more stem cells you deliver to the heart, the greater the benefit that results. Nuclear imaging from clinical stem cell studies have demonstrated that the majority of injected stem cells accumulate in the spleen within one to two hours after injection, and not in the organ desired. While commonly considered a sieve or clearing-site for damaged red blood cells, within the past several years the spleen has been shown to be a critical site for lifelong stem cell generation and storage. Recent clinical nuclear imaging results from stem cell trials confirm this important function of the spleen. Each year 1,000,000 people suffer a heart attack in the US. Almost 6,000,000 people suffer from chronic heart failure, and 700,000 people die from cardiovascular causes each year. Through the use of proprietary technology and intellectual property, AVM Biotech will address this human tragedy through the discovery, development, and commercialization of safe, effective, affordable, and ethical human therapeutics. Summary The company intends to leverage AVM Biotech’s proprietary information and human capital to rapidly generate antibody-based clinical candidates which allow for non-invasive stem cell delivery and increase target organ stem cell retention.
	Home\|Background\|Management\|Advisors\|Vaccines\|Regenerative Medicine\|Media\|Research\|Words of Support \|Contact
Disclaimer \| AVM Biotechnology \| Eklind Hall \| 1102 Columbia Street, Suite 316 \| Seattle, WA 98104 \| 206-906-9922\| \| © Copyright 2010 AVM Biotechnology, LLC



	Programs \| Vaccines \| Regenerative Medicine
	AVM Biotech’s Regenerative Medicine program is dedicated to developing enabling therapies that allow ethical stem cell treatments to realize their full clinical benefit. AVM Biotech certifies that its stem cell therapeutic products are not discovered, screened, evaluated, produced, or tainted in any way by the use of electively aborted human fetal material, human embryonic material, or any other unethically obtained materials. Adult and other morally acceptable stem cell therapies have advanced rapidly into clinical trials, driven primarily by the field of heart disease. Following closely behind the cardiovascular field are stem cell successes in type I diabetes, stroke, multiple sclerosis, muscular dystrophy, and other grievous illnesses. In heart disease, exciting results have been obtained, particularly in the ability of these stem cell treatments to reduce mortality and subsequent hospitalizations after a heart attack. Further improvements in recovery of function and increased quality-of-life after ethical stem cell treatments could be achieved through the development of therapies that 1) enhance the viability of the stem cells administered, 2) that allow for non-invasive delivery of stem cells, or 3) that increase retention of stem cells in the target organ. Regenerative medicine experts uniformly agree that advances in the above areas are essential in order to optimize current stem cell treatment outcomes. AVM Biotech has proprietary information and human capital, derived from Dr. Deisher’s 20 years of experience in pre-clinical research and clinical experience in the areas of heart failure and cardiac regeneration. Clinical target validation for AVM Biotech’s first regenerative medicine project has already been provided by ethical stem cell clinical trials completed by Helmut Drexler in heart attack patients.	Current stem cell treatments largely require the use of invasive and destructive stem cell delivery methods. For instance, stem cells must be directly injected into the heart using surgical methods or delivered into the coronary arteries using invasive catheter techniques, which are themselves damaging. Despite the use of these invasive and destructive delivery methods, only a small percentage of stem cells are retained within the target organ (generally less than 5%). Animal research has demonstrated that the more stem cells you deliver to the heart, the greater the benefit that results. Nuclear imaging from clinical stem cell studies have demonstrated that the majority of injected stem cells accumulate in the spleen within one to two hours after injection, and not in the organ desired. While commonly considered a sieve or clearing-site for damaged red blood cells, within the past several years the spleen has been shown to be a critical site for lifelong stem cell generation and storage. Recent clinical nuclear imaging results from stem cell trials confirm this important function of the spleen. Each year 1,000,000 people suffer a heart attack in the US. Almost 6,000,000 people suffer from chronic heart failure, and 700,000 people die from cardiovascular causes each year. Through the use of proprietary technology and intellectual property, AVM Biotech will address this human tragedy through the discovery, development, and commercialization of safe, effective, affordable, and ethical human therapeutics. Summary The company intends to leverage AVM Biotech’s proprietary information and human capital to rapidly generate antibody-based clinical candidates which allow for non-invasive stem cell delivery and increase target organ stem cell retention.
	Home\|Background\|Management\|Advisors\|Vaccines\|Regenerative Medicine\|Media\|Research\|Words of Support \|Contact
Disclaimer \| AVM Biotechnology \| Eklind Hall \| 1102 Columbia Street, Suite 316 \| Seattle, WA 98104 \| 206-906-9922\| \| © Copyright 2010 AVM Biotechnology, LLC

Programs | Vaccines | Regenerative Medicine